Coxeter-Smith C, Gaglani R, Ingram R, Kidd O, Kumar A, Alhadad A
Transl Gastroenterol Hepatol. 2025; 10:10.
PMID: 39944590
PMC: 11811564.
DOI: 10.21037/tgh-24-87.
Saputra D, Sunat K, Ratnaningsih T
Healthcare (Basel). 2023; 11(5).
PMID: 36900702
PMC: 10000789.
DOI: 10.3390/healthcare11050697.
Spanoudaki A, Papadopoulos N, Trifylli E, Koustas E, Vasileiadi S, Deutsch M
J Multidiscip Healthc. 2022; 15:2301-2309.
PMID: 36247180
PMC: 9562981.
DOI: 10.2147/JMDH.S363177.
AbouBakr O, Ezz El Regal M, Sarhan A, Zaki M, Noaman A
Paediatr Drugs. 2022; 24(5):529-537.
PMID: 35838919
PMC: 9439969.
DOI: 10.1007/s40272-022-00522-1.
Li J, Li G, Wang J, Zhao R, He J, Wang L
Am J Transl Res. 2022; 14(6):3995-4005.
PMID: 35836873
PMC: 9274559.
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Sonsuz A, Bozcan S, Hatemi I, Ozdemir S, Canbakan B, Yildirim S
Turk J Gastroenterol. 2022; 33(5):414-420.
PMID: 35678799
PMC: 11157825.
DOI: 10.5152/tjg.2022.20844.
Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trial.
Wei L, Jia J, Duan Z, Wang F, Niu J, Xie W
JGH Open. 2020; 4(6):1065-1073.
PMID: 33319038
PMC: 7731814.
DOI: 10.1002/jgh3.12387.
Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
Ruiz I, Fourati S, Ahmed-Belkacem A, Rodriguez C, Scoazec G, Donati F
Eur J Gastroenterol Hepatol. 2020; 33(1S Suppl 1):e191-e196.
PMID: 33208686
PMC: 8734617.
DOI: 10.1097/MEG.0000000000002003.
Inhibitors and mortality in persons with nonsevere hemophilia A in the United States.
Lim M, Cheng D, Recht M, Kempton C, Key N
Blood Adv. 2020; 4(19):4739-4747.
PMID: 33007074
PMC: 7556148.
DOI: 10.1182/bloodadvances.2020002626.
Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection.
Puenpatom A, Cao Y, Yu X, Kanwal F, El-Serag H, Kramer J
Infect Dis Ther. 2020; 9(2):355-365.
PMID: 32297307
PMC: 7237563.
DOI: 10.1007/s40121-020-00293-7.
Treatment of Chronic HCV Infection in Patients With Thalassemia.
Bou Daher H, Sharara A
Clin Liver Dis (Hoboken). 2020; 14(6):199-202.
PMID: 32015868
PMC: 6988433.
DOI: 10.1002/cld.853.
Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
Choi D, Puenpatom A, Yu X, Erickson K, Kanwal F, El-Serag H
Antiviral Res. 2019; 174:104698.
PMID: 31862503
PMC: 8724917.
DOI: 10.1016/j.antiviral.2019.104698.
Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy.
Hezode C, Kwo P, Sperl J, Hwang P, Long J, Talwani R
Int J Womens Health. 2019; 11:617-628.
PMID: 31819666
PMC: 6875497.
DOI: 10.2147/IJWH.S203022.
Management of liver complications in sickle cell disease.
Suddle A
Hematology Am Soc Hematol Educ Program. 2019; 2019(1):345-350.
PMID: 31808845
PMC: 6913458.
DOI: 10.1182/hematology.2019000037.
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update.
Smolders E, Jansen A, Ter Horst P, Rockstroh J, Back D, Burger D
Clin Pharmacokinet. 2019; 58(10):1237-1263.
PMID: 31114957
PMC: 6768915.
DOI: 10.1007/s40262-019-00774-0.
Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older.
Flamm S, Peng C, Shibolet O, Nahass R, Hwang P, Barr E
Gerontol Geriatr Med. 2019; 5:2333721418817398.
PMID: 30891470
PMC: 6415929.
DOI: 10.1177/2333721418817398.
Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?.
Bourliere M, Pietri O, Castellani P, Oules V, Adhoute X
Therap Adv Gastroenterol. 2018; 11:1756284818812358.
PMID: 30574189
PMC: 6295690.
DOI: 10.1177/1756284818812358.
Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence.
Morikawa K, Nakamura A, Shimazaki T, Sakamoto N
Drug Des Devel Ther. 2018; 12:2749-2756.
PMID: 30233138
PMC: 6132225.
DOI: 10.2147/DDDT.S133697.
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Clin Mol Hepatol. 2018; 24(3):169-229.
PMID: 30092624
PMC: 6166104.
DOI: 10.3350/cmh.2018.1004.
A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC• Efficacy, Safety, and Pharmacokinetics....
Gastroenterol Hepatol (N Y). 2018; 13(12 Suppl 5):1-24.
PMID: 29950953
PMC: 6015237.
